Viridian Therapeutics (VRDN) News Today $16.09 +0.67 (+4.35%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$16.09 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRDN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by AnalystsViridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating toJune 12 at 5:49 AM | marketbeat.comViridian Therapeutics: The Song Remains The SameJune 9 at 6:31 PM | seekingalpha.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 29.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 115,782 shares oJune 7, 2025 | marketbeat.comViridian Therapeutics to Participate in Upcoming June Investor ConferencesMay 30, 2025 | businesswire.comBank of America Corp DE Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Bank of America Corp DE increased its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 36.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 247,107 shares of the company's stock after purcMay 30, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLCNuveen Asset Management LLC grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 198.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 681,012 shares of the company's stock after acquiring an additional 452,627 shares durMay 28, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Millennium Management LLCMillennium Management LLC lowered its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 45.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 365,972 shares of the company's stock after selling 302,064 shares duringMay 28, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 109,231 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Two Sigma Advisers LP cut its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 24.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 335,569 shares of the company's stock after selling 109,231 shares duMay 27, 2025 | marketbeat.comTwo Sigma Investments LP Sells 57,599 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Two Sigma Investments LP decreased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 424,537 shares of the company's stock after sMay 27, 2025 | marketbeat.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 209,818 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lessened its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 33.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 423,272 shares of the company's stock after sellinMay 22, 2025 | marketbeat.comViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalystsMay 21, 2025 | investing.comSoleus Capital Management L.P. Sells 49,500 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Soleus Capital Management L.P. trimmed its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 52.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4May 21, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Rafferty Asset Management LLCRafferty Asset Management LLC lifted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 90.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 172,960 shares of the company's stock after pMay 21, 2025 | marketbeat.comTang Capital Management LLC Raises Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Tang Capital Management LLC boosted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,492,925 shares of the company's sMay 20, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from BrokeragesViridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and ten have assigned a buMay 20, 2025 | marketbeat.comDeutsche Bank AG Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Deutsche Bank AG boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 402,874 shares of the company's stockMay 20, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $8.47 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)D. E. Shaw & Co. Inc. grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 220.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 442,070 shares of the company's stock after acquiring an additional 304,003 shares during the period.May 18, 2025 | marketbeat.comNorthern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Northern Trust Corp grew its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 19.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 694,142 shares of the company's stock after bMay 18, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Dimensional Fund Advisors LP reduced its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 82.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 55,924 shares of the company's stock afterMay 18, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires New Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN)BNP Paribas Financial Markets acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 203,853 shares of the company'sMay 17, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company raised its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 101.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,720 shares of the company's stock afterMay 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Sells 1,075,610 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Paradigm Biocapital Advisors LP reduced its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 37.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,820,079 shares of the company's stoMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $20.85 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Parkman Healthcare Partners LLC increased its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 155.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,087,634 shares of the company's stockMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $855,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investoMay 16, 2025 | marketbeat.comBalyasny Asset Management L.P. Sells 208,368 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Balyasny Asset Management L.P. trimmed its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 61.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 130,721 shares of the companyMay 15, 2025 | marketbeat.comB. Riley Lifts Earnings Estimates for Viridian TherapeuticsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - B. Riley upped their Q2 2025 EPS estimates for Viridian Therapeutics in a research note issued on Tuesday, May 6th. B. Riley analyst K. Patel now forecasts that the company will post earnings per share of ($0.91) for the quarter, up from tMay 11, 2025 | marketbeat.comHC Wainwright Analysts Cut Earnings Estimates for VRDNViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for shares of Viridian Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($1May 11, 2025 | marketbeat.comQ2 EPS Estimate for Viridian Therapeutics Cut by AnalystViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now expects that the coMay 11, 2025 | marketbeat.comQ2 EPS Forecast for Viridian Therapeutics Boosted by AnalystViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Wedbush increased their Q2 2025 earnings per share estimates for Viridian Therapeutics in a research note issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings per sMay 11, 2025 | marketbeat.comDriehaus Capital Management LLC Decreases Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Driehaus Capital Management LLC lessened its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 5.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,875,876 shares of the company's stock after selliMay 11, 2025 | marketbeat.comQ1 Earnings Forecast for VRDN Issued By HC WainwrightViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Viridian Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao anticipates that the company will earn ($May 10, 2025 | marketbeat.comConcentric Capital Strategies LP Makes New Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Concentric Capital Strategies LP acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 88,527 shares of the company's stock, valued at approximaMay 10, 2025 | marketbeat.comNeedham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00Needham & Company LLC lowered their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a research report on Wednesday.May 9, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) is Deep Track Capital LP's 9th Largest PositionDeep Track Capital LP raised its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 20.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,522,741 shares of the company's stockMay 9, 2025 | marketbeat.comViridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on WednesdayViridian Therapeutics (NASDAQ:VRDN) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-vrdn-stock/)May 9, 2025 | marketbeat.comCrestline Management LP Purchases 48,315 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Crestline Management LP lifted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 31.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,857 shares of the company'sMay 9, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Announces Earnings Results, Beats Expectations By $0.08 EPSViridian Therapeutics (NASDAQ:VRDN - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business's revenue was up .0% compared to the same quarter last year.May 8, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Cutter Capital Management LPCutter Capital Management LP raised its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 21.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 628,677 shares of the company's stock afMay 8, 2025 | marketbeat.comBraidwell LP Buys Shares of 34,094 Viridian Therapeutics, Inc. (NASDAQ:VRDN)Braidwell LP purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 34,094 shares of the company's stock, valued at approximaMay 8, 2025 | marketbeat.comViridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)May 7, 2025 | finance.yahoo.comViridian Therapeutics shares fall as Q1 loss narrows, revenue beatsMay 6, 2025 | in.investing.comViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comNovo Holdings A S Sells 135,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Novo Holdings A S trimmed its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 5.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,250,000 shares of the company's stock after selling 135,00May 3, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Reduces Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Schonfeld Strategic Advisors LLC reduced its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 12.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 670,600 shares of the company's stock after sellMay 3, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lifted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 2,847.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,326,811 shares of the company's stock after acquMay 3, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLCBarclays PLC boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 25.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,860 shares of the company's stock after bMay 2, 2025 | marketbeat.comLord Abbett & CO. LLC Raises Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Lord Abbett & CO. LLC boosted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 17.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 459,588 shares of the company's stock after acquiring an additional 67,630April 30, 2025 | marketbeat.comTower Research Capital LLC TRC Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Tower Research Capital LLC TRC raised its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 824.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,172 shares of the company's stock after purchasinApril 30, 2025 | marketbeat.comArtia Global Partners LP Purchases Shares of 100,000 Viridian Therapeutics, Inc. (NASDAQ:VRDN)Artia Global Partners LP acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 100,000 shares of the company's stock, valued at approximately $1,917,000April 29, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Adage Capital Partners GP L.L.C. increased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 38.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,670,000 shares of the company's stockApril 28, 2025 | marketbeat.com Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Media Mentions By Week VRDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼1.820.88▲Average Medical News Sentiment VRDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼35▲VRDN Articles Average Week Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RDNT News Today BTSG News Today SHC News Today SGRY News Today PRVA News Today CON News Today LFST News Today VCYT News Today ADUS News Today WGS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
